Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0186 • ACR Convergence 2023
Retention in Rheumatology Care and on Hydroxychloroquine and SLE Outcomes by Neighborhood Disadvantage: A Medicare Cohort Study of Acute Care and Kidney Failure
Christie M. Bartels¹, Ang Yu², Felix Elwert², Andrea Gilmore-Bykovskyi³, W. Ryan Powell⁴, Shivani Garg⁵ and Amy J. Kind⁴, ¹University of Wisconsin, School of Medicine and Public Health, Madison, WI, ²Department of Sociology, University of Wisconsin, Madison, WI, ³Berbee Walsh Department of Emergency Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴Center for Health Disparities Research, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁵Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Gaps in systemic lupus (SLE) care are believed to contribute to higher kidney failure (ESKD), acute care use, mortality, and disease damage in US…
Abstract Number: 0469 • ACR Convergence 2023
Hydroxychloroquine and Preeclampsia Risk in Lupus Pregnancy: Results from a Large Regional Integrated Health Network
Julia Simard¹, Emily Liu², Amadeia Rector³, Miranda Cantu⁴, Daniel Kuo⁵, Eliza Chakravarty⁶, Maurice Druzin⁷, Gary Shaw⁷, Michael Weisman⁸ and Monique Hedderson², ¹Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, ²Kaiser Permanente Division of Research, Oakland, CA, ³Stanford University, San Francisco, CA, ⁴Global Lupus Support Group, Portage, MI, ⁵Kaiser Permanente, Redwood City, CA, ⁶Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Stanford University, Stanford, CA, ⁸Stanford, Los Angeles, CA
Background/Purpose: Pregnancies in patients with systemic lupus erythematosus (SLE) are at greater risk of preeclampsia. Hydroxychloroquine (HCQ) is recommended during SLE pregnancy to control disease…
Abstract Number: 0557 • ACR Convergence 2023
Longitudinal Evaluation of Cell-bound Complement Activation Products in Patients with SLE
Jennifer Rogers¹, Amanda Eudy², Daniel Wojdyla³, Tyler O'Malley⁴, David Pisetsky⁵, Roberta Alexander⁴, Kai Sun¹, Lisa Criscione-Schreiber⁶, Jayanth Doss¹, Rebecca Sadun¹, Mithu Maheswaranathan⁶ and Megan Clowse⁷, ¹Duke University, Durham, NC, ²Duke University, Raleigh, NC, ³Duke Clinical Research Institute, Durham, NC, ⁴Exagen, Vista, CA, ⁵Duke University Medical Center, Durham, NC, ⁶Duke University School of Medicine, Durham, NC, ⁷Duke University, Chapel Hill, NC
Background/Purpose: Cell-bound complement activation products (CB-CAPs), when part of a multi-analyte assay with algorithm (MAP), are valuable SLE diagnostic biomarkers. Levels of erythrocyte-bound complement activation…
Abstract Number: 0573 • ACR Convergence 2023
Presence of Mediterranean Fever Gene Variants Provides Protection from the Development of Lupus Nephritis in Patients with Systemic Lupus Erythematosus
Yushiro Endo¹, Tomohiro Koga¹ and Atsushi Kawakami², ¹Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University, Nagasaki, Japan, ²Nagasaki University, Nagasaki, Japan
Background/Purpose: Previous studies showed that the prevalence of variants in Mediterranean Fever (MEFV) genes was lower in adult patients with SLE compared to healthy population…
Abstract Number: 0591 • ACR Convergence 2023
Despite Dramatic Expansion of Approved Biologics in SLE, Unmet Needs Remain
Ryan Rex, Maxine Yarnall and Sawyer May, Spherix Global Insights, Exton, PA
Background/Purpose: This study was conducted to uncover real-world treatment patterns among moderate to severely active systemic lupus erythematosus (SLE) patients in the US.Methods: 1,011 records…
Abstract Number: 0728 • ACR Convergence 2023
Systemic Lupus Erythematosus B Lymphocyte Responsiveness to Type I and Type III Interferon Is Determined by Donor IFN Status and B Cell Phenotype
Diana Alzamareh, Mary O'Connell, Jennifer Anolik and Jennifer Barnas, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Systemic lupus erythematous (SLE) is a heterogenous autoimmune disorder characterized by pathogenic antinuclear antibodies. An interferon (IFN) gene signature and B cell aberrations are…
Abstract Number: 0849 • ACR Convergence 2023
Multiplex Profiling and Machine Learning Reveal Distinct Signatures of Circulating Cytokines Associated with Autoantibody Profiles and Disease Severity in Systemic Lupus Erythematosus
Sarit Pattanaik¹, Ratnadeep Mukherjee², Rina Tripathy³, Birendra Prusty⁴, Balachandran Ravindran⁵ and Bidyut Das⁶, ¹SCB Medical College and Hospital, Cuttack, Odisha, Cuttack, India, ²Norwegian Institute of Public Health, Oslo, Norway, ³Sardar Vallabhbhai Patel Post Graduate Institute of Pediatrics, Cuttack, India, ⁴Fisheries & Animal Resources Development Department, Phulbani, India, ⁵Institute of Life Sciences, Bhubaneswar, India, ⁶SCB medical college, Cuttack, India
Background/Purpose: SLE is one of the leading causes of death in young females suffering from autoimmune disorders. Nephritis, afflicts 60-70% of patients which contribute significantly…
Abstract Number: 0904 • ACR Convergence 2023
KYV-101, a Fully Human Anti-CD19 CAR T Cell Therapy, Demonstrates CAR-Mediated and CD19-Dependent Activity Against Autologous B Cells from Patients with Autoimmune Disease
Soo Park¹, Gloria Lutzny-Geier², Natalia Giltiay¹, Jazmin Bravo¹, Simone Sandoval¹, Joseph Cheng¹, Catherine Dong¹, Nicole Khoshnoodi¹, Ames Register¹, Daniel Anaya¹, Michael Aigner³, Andreas Mackensen³, Georg Schett⁴, Charles Kaplan¹, Dominic Borie¹, James Chung¹ and Tom Van Blarcom⁵, ¹Kyverna Therapeutics, Emeryville, CA, ²Friedrich Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³Department of Internal Medicine 5, Hematology and Oncology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ⁴Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁵Kyverna Therapuetics, Emeryville, CA
Background/Purpose: A significant unmet need remains in the treatment of relapsed and/or refractory B cell-driven autoimmune diseases, including systemic lupus erythematosus (SLE),systemic sclerosis (SSc), and…
Abstract Number: 0925 • ACR Convergence 2023
IL-4 Acts Through Aryl Hydrocarbon Receptor to Antagonize TLR7-induced Double Negative 2 B Cells in Lupus
Changming Lu, Hui-chen Hsu, Min Gao, Jose Rubio, Winn Chatham and John Mountz, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: We recently showed that in SLE, IL-4 suppressed the development of interferon-beta (IFNβ) and TLR7-stimulated T-bet+ double negative 2 (DN2) B cells. Here we…
Abstract Number: 1144 • ACR Convergence 2023
Deucravacitinib in Plaque Psoriasis: Maintenance of Response over 3 Years
Bruce Strober¹, Howard Sofen², Shinichi Imafuku³, Carle Paul⁴, Melinda Gooderham⁵, Lynda Spelman⁶, Seong Jun Seo⁷, Thierry Passeron⁸, Renata M. Kisa⁹, Victoria Berger⁹, Eleni Vritzali¹⁰, Kim Hoyt⁹, Matthew J. Colombo⁹, Subhashis Banerjee⁹, Matthias Augustin¹¹, Linda Stein Gold¹², Andrew Alexis¹³, Diamant Thaçi¹⁴, Andrew Blauvelt¹⁵ and Mark Lebwohl¹⁶, ¹Yale University, New Haven, CT, ²University of California Los Angeles School of Medicine and Dermatology Research Associates, Los Angeles, CA, ³Fukuoka University Faculty of Medicine, Fukuoka, Japan, ⁴Toulouse University and CHU, Toulouse, France, ⁵SKiN Centre for Dermatology, Ontario, Canada, ⁶Veracity Clinical Research, Brisbane, Australia, ⁷Chung-Ang University Hospital, Seoul, South Korea, ⁸Université Côte d’Azur, University Hospital of Nice, Nice, France, ⁹Bristol Myers Squibb, Princeton, NJ, ¹⁰Bayer, Sissach, Switzerland, ¹¹Institute of Health Care Research in Dermatology and Nursing, Hamburg, Germany, ¹²Henry Ford Health System, MI, ¹³Weill Cornell Medicine, New York, NY, ¹⁴Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ¹⁵Oregon Medical Research Center, Portland, OR, ¹⁶Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in multiple countries for the treatment of adults with plaque psoriasis. Deucravacitinib…
Abstract Number: 1249 • ACR Convergence 2023
Cross-Sectional Associations of Emotional Distress and Cardiovascular Health in Juvenile Lupus and Dermatomyositis
Kaveh Ardalan¹, Angel Davalos¹, Hwanhee Hong¹, Bryce Reeve¹, Christoph Hornik¹, M. Anthony Moody¹, Donald Lloyd-Jones², Eveline Wu³, Audrey Ward¹, Rebecca Sadun⁴, Jeffrey Dvergsten⁵, Ann Reed⁶, Mark Connelly⁷ and Laura Schanberg¹, ¹Duke University School of Medicine, Durham, NC, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³University of North Carolina School of Medicine, Chapel Hill, NC, ⁴Duke University, Durham, NC, ⁵Duke University School of Medicine, Hillsborough, NC, ⁶Duke University School of Medicine, Chapel HIll, NC, ⁷Children's Mercy Kansas City / University of Missouri-Kansas City School of Medicine, Kansas City, MO
Background/Purpose: Juvenile lupus (JSLE) and dermatomyositis (JDM) patients are at high risk for cardiovascular disease (CVD). The American Heart Association cardiovascular health (CVH) construct is…
Abstract Number: 1447 • ACR Convergence 2023
Increased Left Ventricular Mass Index in Systemic Lupus Erythematosus Patients with Lupus Nephritis Compared to Those Without Nephritis
Natalia Guajardo-Jauregui¹, Dionicio A. Galarza-Delgado², Iris Colunga², José Ramón Azpiri-López², Rosa Arvizu-Rivera³ and Jesus Alberto Cardenas-De la Garza⁴, ¹Hospital Universitario Dr. José Eleuterio González, Monterrey, Mexico, ²Hospital Universitario UANL, Monterrey, Mexico, ³Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico
Background/Purpose: Patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN) are at increased risk of cardiovascular (CV) morbidity and mortality, compared to those without…
Abstract Number: 1464 • ACR Convergence 2023
Lupus Flares More Common in Patients on Dialysis Compared to After Renal Transplant: A Systematic Review and Meta-analysis
Omer Pamuk¹, Ansaam Daoud², Loai Dweik³, Niraj Desai⁴ and sarfaraz Hasni⁵, ¹University Hospitals Cleveland Medical Center, Cleveland, OH, ²University Hospitals, Case Western Reserve University, Akron, OH, ³Cleveland Clinic Akron General, Akron, OH, ⁴Case Western Reserve University / University Hospitals Cleveland Medical Center, Cleveland, OH, ⁵Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: End-stage renal disease (ESRD) may develop in up to 20% of patients with lupus nephritis (LN). The SLE disease activity generally declines after the…
Abstract Number: 1481 • ACR Convergence 2023
Racial Disparities in Lupus Nephritis: A Nationwide Analysis
Faria Sami¹, Shahzad Ahmed Sami², Augustine Manadan³ and Shilpa Arora¹, ¹John H. Stroger Jr. Hospital of Cook County, Chicago, IL, ²Trinity Health Oakland Hospital, Chicago, IL, ³Rush University Medical Center, Chicago, IL
Background/Purpose: Lupus nephritis (LN) is a significant predictor of morbidity and mortality in Systemic Lupus Erythematosus (SLE). Racial disparities are known to exist in SLE…
Abstract Number: 1498 • ACR Convergence 2023
First-in-Human Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of DS-7011a, an Anti-TLR7 Antagonistic Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus
Giorgio Senaldi¹, Aparna Mohan¹, Li Zhang¹, Jun Tanaka², Grishma Pandya³, Sindee Grossman³, Sarah Urbina⁴, Steven Reynolds⁵ and Alan Hand⁴, ¹Daiichi Sankyo, Basking Ridge, NJ, ²Daiichi Sankyo, Inc., Basking Ridge, NJ, ³Daiichi Sankyo Inc., Basking Ridge, NJ, ⁴Worldwide Clinical Trials, San Antonio, TX, ⁵Cenexel, Los Alamitos, CA
Background/Purpose: Toll-like receptor (TLR)7 is a pattern recognition receptor, whose ligands include nucleic acids and whose activation is part of the pathogenesis of systemic lupus…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].